The global naloxone market is estimated to be valued at USD 1,341.5 MN in 2024 and is expected to exhibit a CAGR of 10.4% during the forecast period (2024-2031). Naloxone is an opioid antagonist used for the complete or partial reversal of opioid overdose. It works by competitively binding to opioid receptors and reversing and blocking the effects of other opiates. Naloxone has become an integral part of emergency medical treatment for opioid overdoses. With the ongoing opioid crisis in many parts of the world, the prevalence of opioid abuse has increased massively in recent times. As a result, the need for readily available naloxone formulations has grown for emergency treatment. This factor is expected to largely influence the growth trajectory of the global naloxone market in the coming years.

Market Dynamics:

The global naloxone market is primarily driven by the rising incidence of opioid overdose cases worldwide. According to the National Institute on Drug Abuse, opioid overdose mortality rates in the U.S. increased by over 130% between 2000 and 2019. Moreover, the COVID-19 pandemic further exacerbated the impact of social isolation on psychological health and increased opioid misuse in many countries. A high demand for user-friendly naloxone delivery formulations like nasal sprays and auto-injectors from both healthcare and law enforcement agencies is fueling the market growth. However, adverse side effects associated with naloxone therapy and the availability of alternative treatment options are limiting market expansion. Ongoing R&D into the development of long-acting naloxone formulations present lucrative opportunities for key players in the future.

Key Features of the Study:

• This report provides an in-depth analysis of the global naloxone market, and provides market size (US$ MN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global naloxone market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes EMERGENT, Indivior PLC, Akorn, Inc, Hikma Pharmaceuticals PLC, Viatris Inc., Sandoz, Teva Pharmaceuticals, Amphastar Pharmaceuticals, Inc., Kaleo, Inc., Pfizer Inc., Amneal Pharmaceuticals, Viatris Inc., Somerset Pharma, LLC, Orexo AB, and UCB Pharma.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global naloxone market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global naloxone market.

Market Segmentation

• Strength:
  • 2.0 mg/ml
  • 1 mg/ml
  • 0.4 mg/ml
  • Others   
• Route of Administration:
  • Intranasal
  • Injectable
    • Intramuscular
    • Subcutaneous
    • Intravenous 
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:                    
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • EMERGENT
  • Indivior PLC
  • Akorn, Inc
  • Hikma Pharmaceuticals PLC
  • Viatris Inc.
  • Sandoz
  • Teva Pharmaceuticals
  • Amphastar Pharmaceuticals, Inc.
  • Kaleo, Inc.
  • Pfizer Inc.
  • Amneal Pharmaceuticals
  • Viatris Inc.
  • Somerset Pharma, LLC
  • Orexo AB
  • UCB Pharma